Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Friendship Bench Plus Trial for Depression in Zimbabwe
NCT06384209Recruiting
- Sponsor
- University of Bern
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of fluoxetine and sertraline in major depressive disorder (MDD) (2 arms), sponsored by University of Bern. Primary endpoint: Treatment response (>= 50% improvement in PHQ-9) at 3 months. Started Jun 2025; status: recruiting.
02
Drugs
fluoxetinesertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06384209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384209.